OPB-31121 / Otsuka - LARVOL DELTA

Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma (clinicaltrials.gov) - P1 | N=7 | Completed | Sponsor: Otsuka Beijing Research Institute | Unknown status ➔ Completed | N=42 ➔ 7

Enrollment change • Trial completion • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways. (PubMed, Clin Lymphoma Myeloma Leuk) - "Binding of tumor cells to stromal cells prompts cytokine production of stromal cells and launches various signaling pathways such as Janus-activated kinase/signal transduction and activator of transcription, Ras/Raf/MEK/mitogen-activated protein kinase, phosphatidyl inositol 3-kinase/AKT, and NF-KB, which ultimately lead to the high survival rate and drug resistance in tumor cells. Thus, combining various drugs such as bortezomib, dexamethasone, lenalidomide, and melphalan with compounds that are not common, including CTY387, LLL-12, OPB31121, CNTO328, OSI-906, FTY720, triptolide, and AV-65, could be one of the most effective treatments for these patients."

Journal • Review